Biallelic mutation in MYH7 and MYBPC3 leads to severe cardiomyopathy with left ventricular noncompaction phenotype.
Adolescent
Adult
Cardiac Myosins
/ genetics
Cardiomyopathy, Hypertrophic
/ genetics
Carrier Proteins
/ genetics
Female
Haploinsufficiency
Heart Transplantation
Humans
Infant
Isolated Noncompaction of the Ventricular Myocardium
/ genetics
Loss of Function Mutation
Male
Mutation, Missense
Myosin Heavy Chains
/ genetics
Pedigree
Phenotype
Young Adult
MYBPC3
MYH7
biallelic mutation
haploinsufficiency
left ventricular noncompaction cardiomyopathy
Journal
Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
04
12
2018
revised:
21
03
2019
accepted:
26
03
2019
pubmed:
30
3
2019
medline:
31
3
2020
entrez:
30
3
2019
Statut:
ppublish
Résumé
Dominant mutations in the MYH7 and MYBPC3 genes are common causes of inherited cardiomyopathies, which often demonstrate variable phenotypic expression and incomplete penetrance across family members. Biallelic inheritance is rare but allows gaining insights into the genetic mode of action of single variants. Here, we present three cases carrying a loss-of-function (LoF) variant in a compound heterozygous state with a missense variant in either MYH7 or MYBPC3 leading to severe cardiomyopathy with left ventricular noncompaction. Most likely, MYH7 haploinsufficiency due to one LoF allele results in a clinical phenotype only in compound heterozygous form with a missense variant. In contrast, haploinsufficiency in MYBPC3 results in a severe early-onset ventricular noncompaction phenotype requiring heart transplantation when combined with a de novo missense variant on the second allele. In addition, the missense variant may lead to an unstable protein, as overall only 20% of the MYBPC3 protein remain detectable in affected cardiac tissue compared to control tissue. In conclusion, in patients with early disease onset and atypical clinical course, biallelic inheritance or more complex variants including copy number variations and de novo mutations should be considered. In addition, the pathogenic consequence of variants may differ in heterozygous versus compound heterozygous state.
Substances chimiques
Carrier Proteins
0
MYH7 protein, human
0
myosin-binding protein C
0
Cardiac Myosins
EC 3.6.1.-
Myosin Heavy Chains
EC 3.6.4.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1101-1114Subventions
Organisme : Interdisciplinary Center for Clinical Research (IZKF) Würzburg
ID : E-338
Pays : International
Organisme : Federal Ministry of Education and Research (BMBF) Berlin, Germany
ID : 1GI0601
Pays : International
Organisme : Federal Ministry of Education and Research (BMBF) Berlin, Germany
ID : 01EO1504
Pays : International
Organisme : Supported by the DZHK (German Centre for Cardiovascular Research)
ID : 81X2100230
Pays : International
Organisme : Supported by the DZHK (German Centre for Cardiovascular Research)
ID : 81Z31100333
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.